

HIV-Associated Avascular Necrosis

Audrey Li, MD

Assistant Professor of Medicine, University of Washington School of Medicine

Last Updated: 1/11/2026

Disclosures

Contracted research through UW Positive Research on ViiV ART trials
(CROWN, CUATRO)

Disclaimer

Funding for this presentation was made possible by TR7HA53202 from the Human Resources and Services Administration's (HRSA) HIV/AIDS Bureau (HAB). The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. *Any trade/brand names for products mentioned during this presentation are for training and identification purposes only.*

A Case

- 62F with well-controlled HIV (CD4 1047/41%, VLUD) on TLD presents to establish care after moving to this area.
- Diagnosed 10 years ago on routine screening, started on EFV/TDF/FTC and then transitioned to DTG/TDF/3TC some years ago
- Notes that she has had chronic L hip pain for several years, which developed after a fall, but previously had been active and working as a caregiver
- Has been gradually worsening, now to an unbearable degree
- In the past week, she has been unable to ambulate ☹️

Imaging



- **XR Pelvis:** There is deformity and sclerosis of the left femoral head. Findings may reflect avascular necrosis of head due to prior fracture deformity vs sequela of septic joint, or may be from superimposed overhanging osteophytes.
- **CT Pelvis:** Severe left hip osteoarthritis. Left femoral head collapse secondary to avascular necrosis.

Learning Objectives

- Review epidemiology of HIV-associated avascular necrosis.
- Understand the potential mechanisms for increased risk in PWH.
- Recognize how to diagnose HIV-associated avascular necrosis.
- Discuss management options.

Background

- First described in PWH in 1990 via case reports
- Now recognized to be far more common
 - Yearly incidence of symptomatic osteonecrosis:¹
 - General population: 0.003 to 0.006 cases per 100 person-years
 - PWH: 0.03 to 0.37 cases per 100 person-years
 - 2001 natural history study at NIH showed 4.4% prevalence in asymptomatic PWH¹
 - 2017 EuroSIDA multinational prospective cohort study showed 0.6% prevalence²
 - 2025 retrospective study in S.Africa showed that of 1400 patients s/p elective primary THA at a tertiary care center (2015-2021), 11% were for HIV-associated AVN³
- Occurs earlier in PWH
- Less commonly responsive to conservative measures in PWH

A Refresher on AVN

- Also called osteonecrosis, aseptic necrosis, ischemic necrosis
- Bone death occurs due to interrupted blood supply
- Mechanism still poorly understood and controversial
 - Genetic predisposition? Metabolic factors? Mechanical stresses?
 - Interrupted blood supply → Adjacent hyperemia to attempt repair → Reactive angiogenesis → Impairment of angiogenesis leads to demineralization, trabecular thinning, collapse
- Can be precipitated by direct damage to bone vasculature (e.g. femoral neck fracture) or marrow (e.g. radiation)
- Other less direct mechanisms poorly understood

Risk Factors and Pathogenesis

- **Modifiable factors:**

- Excess alcohol intake
- Cigarette smoking
- Testosterone therapy?⁴
- Decompression disease

- **Other disease states:**

- Glucocorticoid usage
- Sickle cell hemoglobinopathies
- Dyslipidemia?

- **HIV:**

- History of AIDS-defining conditions
- Lower CD4
- *Lipid dysfunction?*
- *Inflammatory pathways?*

- **ART:**

- TDF/FTC especially if >1y^{2,5}
- Maybe past exposure to early PIs?^{2,6}

Management of HIV AVN

- **Symptomology**


- Gradual onset of hip or groin pain
- Worse with weight bearing
- Can be bilateral and multifocal in PWH
- Common sites: hip, shoulder

- **Imaging**

- XR may be normal, especially if early
- MRI is gold standard for diagnosis
- Both sides should be imaged even if no sx

- **Management**

- Joint replacement (total hip arthroplasty) is needed in many cases



References

1. Morse CG et al. « The incidence and natural history of osteonecrosis in HIV-infected adults.» *CID*. 2007 Mar 1; 44(5):739-48. [PMID: 17278070](#)
2. Borges AH et al. « Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort.» *CID*. 2017 May 15;64(10):1413-1421. [PMID: 28329090](#)
3. Geldenhuys DB et al. « An increased incidence of avascular necrosis as the predisposing aetiology for primary total hip arthroplasty in sub-Saharan Africa – a retrospective review of 1,400 consecutive patients. » *SICOT J*. 2025;11:54. [PMID: 40990380](#)
4. Vabre C et al. « Testosterone treatment and the risk of osteonecrosis: a pharmacovigilance analysis in Vigibase. » *Eur J Clin Pharm*. 2023 Mar;79(3):383-388. [PMID: 36602591](#)
5. Bayard C et al. « Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. » *OFID*. 2017 Aug 22;4(4):ofx177. [PMID: 29026869](#)
6. Permpalung N et al. « Protease inhibitors and avascular necrosis: a systematic review and meta-analysis. » *Int J Antimicrob Agents*. 2014 Aug;44(2):93-95. [PMID: 24726526](#)
7. Miller KD et al. « High Prevalence of Osteonecrosis of the Femoral Head in HIV-Infected Adults. » *Ann Intern Med*. 2002 Jul 2;137(1):17-25. [PMID: 12093241](#)
8. Horberg M et al. « Primary Care Guidance for Providers of Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America. » *CID*. 2024 Oct 12:ciae479. [PMID: 39393187](#)

Acknowledgment

This Mountain West AIDS Education and Training (MWAETC) program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of award TR7HA53202 totaling \$2,820,772 with 0% financed with non-governmental sources.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.